PMID- 11112863
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20220409
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 123
IP  - 3
DP  - 2000 Nov
TI  - MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with 
      asthma and chronic obstructive pulmonary disease.
PG  - 259-67
AB  - BACKGROUND: The course of asthma and chronic obstructive pulmonary disease (COPD) 
      is associated with bronchial morphological changes. Metalloproteinases are 
      thought to play a role in these structural changes. METHODS: We studied the 
      gelatinolytic activity present in the induced sputum from 20 patients with 
      asthma, 20 with COPD and 19 healthy controls. The assessment of gelatinolytic 
      activity was performed by quantitative zymography, and gelatinolytic species were 
      identified by Western blot analysis. Tissue inhibitor of metalloproteinase-1 
      (TIMP-1) was detected by reverse zymography and ELISA. RESULTS: From zymography, 
      we found significantly higher gelatinolytic activity linked to pro-matrix 
      metalloproteinase-9 (pro-MMP-9) in the sputum from asthmatics (p < 0.0001) and 
      COPD patients (p < 0.0001) compared to the control group. Furthermore, the 
      activated form of MMP-9 (85 kD) was found in the sputum from 60% of asthmatics 
      and 85% of COPD patients, but was absent in that of control subjects (p < 
      0.0001). Importantly, although less frequently detectable than pro-MMP-9, pro- 
      MMP-2 (72 kD) was found more frequently in asthmatics (50%) than in control 
      subjects (5%) (p < 0. 005). We also described two unusual gelatinolytic species 
      of 45 and 120 kD and showed that they derived from MMP-9 according to their 
      ability to bind gelatin and anti-MMP-9 antibody. Levels of TIMP-1 were higher in 
      asthmatics (p < 0.05) and COPD patients (p < 0.05) than in controls. CONCLUSION: 
      Asthmatics and COPD patients display an increased gelatinolytic activity linked 
      to MMP-2 and MMP-9 and higher levels of TIMP-1 in their sputum.
CI  - Copyright 2000 S. Karger AG, Basel
FAU - Cataldo, D
AU  - Cataldo D
AD  - Department of Pneumology, University of Liege, Liege, Belgium. 
      Didier.Catalado@ulg.ac.be
FAU - Munaut, C
AU  - Munaut C
FAU - Noel, A
AU  - Noel A
FAU - Frankenne, F
AU  - Frankenne F
FAU - Bartsch, P
AU  - Bartsch P
FAU - Foidart, J M
AU  - Foidart JM
FAU - Louis, R
AU  - Louis R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Protease Inhibitors)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 9000-70-8 (Gelatin)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Asthma/*metabolism
MH  - Female
MH  - Gelatin/metabolism
MH  - Humans
MH  - Lung Diseases, Obstructive/*metabolism
MH  - Male
MH  - Matrix Metalloproteinase 2/*analysis
MH  - Matrix Metalloproteinase 9/*analysis
MH  - Middle Aged
MH  - Protease Inhibitors/analysis
MH  - Sputum/*metabolism
MH  - Tissue Inhibitor of Metalloproteinase-1/analysis
EDAT- 2000/12/12 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/12/12 11:00
PHST- 2000/12/12 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/12/12 11:00 [entrez]
AID - iaa23259 [pii]
AID - 10.1159/000024452 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2000 Nov;123(3):259-67. doi: 10.1159/000024452.